Key Developments For Telik Inc
Telik Inc (TELK.O) (Consolidated Issue listed on NASDAQ Global Market)
Telik, Inc. Announces Publication Of Positive Phase 1-2a Results Of Multicenter Study Of TELCYTA In Combination With Carboplatin and Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer
Telik, Inc. announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10. One hundred twenty-nine patients were treated with TELCYTA in combination with carboplatin and paclitaxel, of whom 100 were continuing to respond at the end of combination therapy and eligible to receive single agent TELCYTA maintenance therapy. Those patients who received the TELCYTA combination therapy followed by TELCYTA maintenance therapy vs. no maintenance therapy had a median progression-free survival (PFS) of 6.8 months vs. 3.9 months, respectively (p< 0.0001). The difference in PFS correlated with a median survival of 16.8 months in the maintenance group vs. 8.8 months for those without maintenance therapy (p<0.0001). TELCYTA in combination with carboplatin and paclitaxel chemotherapy followed by TELCYTA maintenance therapy was well tolerated. TELCYTA may be suited to application as maintenance therapy, an area of current intense interest for the treatment of lung cancer patients. In addition, the regimen appeared active across all types of NSCLC and ongoing investigations are attempting to identify the characteristics of the NSCLC population most likely to benefit from this approach.
Telik, Inc. Announces Publication of Positive Phase 1 Results of Multicenter Study of Ezatiostat Hydrochloride Tablets In Patients With Myelodysplastic Syndrome
Telik, Inc. announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS). Also announces positive results from a separate Phase 1-2a study in MDS patients involving an intravenous formulation of TELINTRA. The findings reported from these studies support the further development of TELINTRA. Phase 2 studies are ongoing in MDS (enrollment completion expected by year end), and Severe Chronic Idiopathic Neutropenia.
Telik, Inc. Presents Results At ASCO From ASSIST-5 Trial Of TELCYTA In Platinum Refractory And Resistant Ovarian Cancer
Telik, Inc. announced the results from the ASSIST-5 Phase 3 randomized, multinational study of TELCYTA (canfosfamide HCl) in combination with pegylated liposomal doxorubicin vs. PLD alone in second-line therapy in platinum refractory or resistant ovarian cancer. The trial design provided for the enrollment of 244 patients. The trial was interrupted by a clinical hold from June 2007 until October 2007. At the time of the clinical hold, 125 patients had been enrolled in the trial. As a result, 35 patients (21 on the combination treatment and 14 on PLD alone) were discontinued from their study treatment(s) and did not complete their assigned per protocol therapy. Although enrollment was permitted after the release of the clinical hold, Telik decided not to enroll additional patients, which impacted the powering of the study. Patient Demographics: The treatment arms were well-balanced for patient demographics and key ovarian cancer disease characteristics, including age, ECOG Performance Status, presence of bulky disease and history of prior taxane therapy. A greater number of patients (13, 20%) had platinum refractory disease on the TELCYTA plus PLD arm compared to (8, 13%) with the PLD arm. Efficacy Results: On an Intent-to-Treat basis for the entire 125 enrolled patients, including those affected by the hold, the median progression-free survival was 5.6 months on the TELCYTA plus PLD arm compared to 3.7 months on the PLD control arm, p=0.7243 and hazard ratio (HR)=0.92.
Telik, Inc. Announces New TRAP Drug Discovery Agreement
Telik, Inc. announced an agreement to provide its TRAP drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS studies the mechanisms underlying musculoskeletal and autoimmune diseases to discover effective treatments for these disorders. HSS investigators will use Telik's TRAP technology to discover compounds that inhibit a key enzyme in cell signaling and migration.
Carl Icahn Cuts Telik, Inc. Stake To 4.81% From 8.15%-DJ
Dow Jones reported that Carl Icahn cutting his stake in Telik, Inc. to 4.81% from 8.15%. Entities affiliated with Icahn reduced their holdings in Telik, Inc. to 2.56 million shares from about 4.34 million shares as reported on October 24, according to a filing with the Securities and Exchange Commission.
